KR20160065985A - 전립선 암 치료를 위한 mva의 용도 - Google Patents

전립선 암 치료를 위한 mva의 용도 Download PDF

Info

Publication number
KR20160065985A
KR20160065985A KR1020167013629A KR20167013629A KR20160065985A KR 20160065985 A KR20160065985 A KR 20160065985A KR 1020167013629 A KR1020167013629 A KR 1020167013629A KR 20167013629 A KR20167013629 A KR 20167013629A KR 20160065985 A KR20160065985 A KR 20160065985A
Authority
KR
South Korea
Prior art keywords
mva
seq
pap
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167013629A
Other languages
English (en)
Korean (ko)
Inventor
알랭 델카이레
라이너 라우스
스테파니 만들
라이언 블래어 로운트리
파테마 레그랜드
Original Assignee
버베리안 노딕 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버베리안 노딕 에이/에스 filed Critical 버베리안 노딕 에이/에스
Publication of KR20160065985A publication Critical patent/KR20160065985A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194Prostate specific antigen [PSA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/884Vaccine for a specifically defined cancer prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/04Uses of viruses as vector in vivo
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167013629A 2007-10-18 2008-10-16 전립선 암 치료를 위한 mva의 용도 Ceased KR20160065985A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96089307P 2007-10-18 2007-10-18
US60/960,893 2007-10-18
PCT/US2008/080229 WO2009052328A1 (en) 2007-10-18 2008-10-16 Use of mva to treat prostate cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107010873A Division KR101648087B1 (ko) 2007-10-18 2008-10-16 전립선 암 치료를 위한 mva의 용도

Publications (1)

Publication Number Publication Date
KR20160065985A true KR20160065985A (ko) 2016-06-09

Family

ID=40342626

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167013629A Ceased KR20160065985A (ko) 2007-10-18 2008-10-16 전립선 암 치료를 위한 mva의 용도
KR1020107010873A Expired - Fee Related KR101648087B1 (ko) 2007-10-18 2008-10-16 전립선 암 치료를 위한 mva의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107010873A Expired - Fee Related KR101648087B1 (ko) 2007-10-18 2008-10-16 전립선 암 치료를 위한 mva의 용도

Country Status (13)

Country Link
US (2) US7867483B2 (cg-RX-API-DMAC7.html)
EP (1) EP2207564B1 (cg-RX-API-DMAC7.html)
JP (1) JP5669581B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160065985A (cg-RX-API-DMAC7.html)
CN (1) CN101888853B (cg-RX-API-DMAC7.html)
AU (1) AU2008312444B2 (cg-RX-API-DMAC7.html)
CA (1) CA2702586C (cg-RX-API-DMAC7.html)
DK (1) DK2207564T3 (cg-RX-API-DMAC7.html)
ES (1) ES2608604T3 (cg-RX-API-DMAC7.html)
IL (1) IL204541A (cg-RX-API-DMAC7.html)
NZ (2) NZ584042A (cg-RX-API-DMAC7.html)
RU (1) RU2499606C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009052328A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体
CA2698343C (en) * 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
JP5951929B2 (ja) * 2007-10-03 2016-07-13 コーネル ユニヴァーシティー Psma抗体を用いる増殖性障害の治療
NZ584042A (en) * 2007-10-18 2012-09-28 Bn Immunotherapeutics Inc Use of mva to treat prostate cancer
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
EP2398504B1 (en) * 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
JP6312141B2 (ja) 2012-03-30 2018-04-18 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
PT3062815T (pt) * 2013-11-01 2019-03-27 Pfizer Vetores para expressão de antigénios associados à próstata
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. キメラ抗原受容体
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
JP2018537411A (ja) * 2015-10-02 2018-12-20 ユニバーシティ オブ コペンハーゲン ヒストン読み取りドメイン遮断低分子
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
JP2019512020A (ja) 2016-02-12 2019-05-09 マディソン ヴァクシーンズ インコーポレイテッド がんの治療
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS
TWI746545B (zh) * 2016-04-26 2021-11-21 日商大日本住友製藥股份有限公司 經取代嘌呤衍生物
JP6983819B2 (ja) * 2016-06-03 2021-12-17 エトゥビクス コーポレーション 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法
EP3462853B1 (en) 2016-06-03 2023-03-01 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
CN106084027A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3980071A4 (en) * 2019-06-07 2023-10-11 Oregon Health & Science University Tumor-associated antigen-specific t cell responses
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
US20210315986A1 (en) * 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009052A2 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585103A (en) * 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
WO1998004689A1 (en) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
JP2001516226A (ja) 1997-04-11 2001-09-25 デンドレオン コーポレイション 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法
JP2002526419A (ja) * 1998-10-05 2002-08-20 ファーメクサ エイ/エス 治療上のワクチン注射のための新規な方法
ATE361988T1 (de) * 1998-12-09 2007-06-15 Us Gov Health & Human Serv Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7718166B2 (en) * 2002-03-01 2010-05-18 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille Calmette-Guerin expressing prostate specific antigens
EP1407033B1 (en) * 2002-05-16 2006-01-11 Bavarian Nordic A/S Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
EP1660664A4 (en) * 2003-08-21 2008-02-13 Virax Dev Pty Ltd POXVIRUS VECTOR ENCODING SPECIFIC PROSTATE ANTIGENS FOR THE TREATMENT OF PROSTATE CANCER
BRPI0401465A (pt) 2004-04-20 2006-02-21 Embria Informatica Ltda sistema para administrar interações entre usuários e aplicações de software em um ambiente web
NZ584042A (en) 2007-10-18 2012-09-28 Bn Immunotherapeutics Inc Use of mva to treat prostate cancer

Also Published As

Publication number Publication date
ES2608604T3 (es) 2017-04-12
IL204541A (en) 2015-02-26
WO2009052328A1 (en) 2009-04-23
JP5669581B2 (ja) 2015-02-12
RU2010115220A (ru) 2011-11-27
EP2207564B1 (en) 2016-10-05
JP2011500718A (ja) 2011-01-06
DK2207564T3 (en) 2017-01-16
RU2499606C2 (ru) 2013-11-27
KR20100109545A (ko) 2010-10-08
HK1149709A1 (en) 2011-10-14
CA2702586C (en) 2017-08-01
US20110008386A1 (en) 2011-01-13
AU2008312444A1 (en) 2009-04-23
AU2008312444B2 (en) 2014-02-06
US8377688B2 (en) 2013-02-19
NZ601827A (en) 2014-01-31
CA2702586A1 (en) 2009-04-23
CN101888853A (zh) 2010-11-17
IL204541A0 (en) 2010-11-30
KR101648087B1 (ko) 2016-08-17
CN101888853B (zh) 2013-03-13
US20090104225A1 (en) 2009-04-23
WO2009052328A8 (en) 2009-07-02
EP2207564A1 (en) 2010-07-21
NZ584042A (en) 2012-09-28
US7867483B2 (en) 2011-01-11

Similar Documents

Publication Publication Date Title
KR101648087B1 (ko) 전립선 암 치료를 위한 mva의 용도
JP7368305B2 (ja) 腫瘍抗原を発現するポックスウイルス及びtim-3に対するモノクローナル抗体を用いた癌治療のための併用療法
US7807146B2 (en) Methods for treating cancer with a recombinant MVA expressing HER-2
JP6747981B2 (ja) 腫瘍抗原発現組換えポックスウイルス及び免疫チェックポイント分子アンタゴニストまたはアゴニストを用いた癌治療のための併用療法
US20150283220A1 (en) Methods and compositions for the treatment of cancer
HK1149709B (en) Use of mva to treat prostate cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160523

Application number text: 1020107010873

Filing date: 20100518

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160620

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160625

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161011

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160625

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I